Doox Medica has signed an agreement to distribute Cappella's Sideguard Coronary Stent system in the Middle Eastern territories.
The Sideguard incorporates the company’s proprietary stent design and balloon delivery system and its sidebranch technology offers interventional cardiologists a solution that preserves the sidebranch of diseased coronary arteries by protecting the ostium while minimizing plaque shift.
With a strategy to accelerate commercialization, Cappella is also seeking market entry of its Sideguard product in India.
Cappella’s commitment to India will in the longer term extend to clinical trials of its next generation of products currently under development that will result in additional commercialization opportunities.
The company also annonced that its Sideguard Coronary Stent system has been approved by the Saudi Food and Drug Administration (FDA).